Compare Johnson & Johnson (JNJ) vs Phillips 66 (PSX) Price & Performance

Johnson & Johnson (JNJ) trades at $250.61, down 0.96% on the day, with a bullish technical signal and strong fundamental performance. Recent Q2 2026 earnings beat expectations with EPS of $2.90 versus $2.84 expected, and revenue growth of 6.6% year-over-year. The stock shows robust profitability with a net income margin of 21.48% and ROE of 26.42%, supported by consistent dividend payments including the recent $1.34 per share declared for H1-2026.

JNJ presents a favorable investment case with analyst consensus price target of $279.33 implying ~11% upside, though rising debt-to-asset ratio to 24.06% in 2025 and volatile cash flow trends pose risks. The healthcare giant's diversified portfolio and raised full-year guidance underpin long-term stability, but investors should monitor execution amid competitive and regulatory pressures.

Phillips 66 (PSX) trades at $212.27, up 2.62% today, with a bullish technical signal and strong analyst support. Recent earnings beats, including Q1 2026's positive surprise, highlight operational strength amid volatile energy markets. The stock benefits from robust refining margins and disciplined capital returns, including a $1.27 quarterly dividend. Valuation metrics like a P/E of 20.63 and P/S of 0.63 suggest relative affordability compared to sector peers.

Outlook remains positive due to tight fuel markets and efficient refining operations, though risks include oil price volatility and declining revenue trends. With 57% of analysts rating it a buy and a consensus price target of $201.50, the stock offers upside potential, but investors should monitor debt levels and macroeconomic pressures on energy demand.